The FDA has approved a novel combination therapy using Lumakras® (sotorasib) and Vectibix® (panitumumab) for adults with KRAS ...
Oncolytics Biotech received approval from Germany\u2019s Paul-Ehrlich-Institute to advance Cohort 5 of the GOBLET study, ...
Ariceum Therapeutics announced that the FDA has cleared its investigational new drug application to commence a Phase I/II ...
The Internet of Medical Things (IoMT) is set to radically change the quality of care and outcomes for millions of patients, ...
Artificial Intelligence (AI) can play a crucial role in drug discovery, but the lack of sufficient data in this area remains ...
Novartis announced that its drug Ribociclib (Kisqali®) combined with endocrine therapy (ET) demonstrates a sustained 28.5% reduction in distant recurrence for high-risk HR+/HER2- early breast cancer ...
The US FDA has approved BRAFTOVI® (encorafenib) with cetuximab and mFOLFOX6 as a first-line therapy for BRAF V600E-mutant metastatic colorectal cancer. The Phase 3 BREAKWATER trial showed ...
AbbVie has announced plans to acquire Nimble Therapeutics in a $200 million deal. The acquisition brings Nimble’s pioneering oral peptide IL23R inhibitor, currently in preclinical development for ...
The FDA has approved tirzepatide (Zepbound) as the first and only medication for obstructive sleep apnea (OSA) in adults with obesity. Clinical trials revealed that tirzepatide achieved an average ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback